Purpose: To evaluate progression rates with dorzolamide compared with other hypotensive agents in primary open-angle glaucoma.
Methods: Patients who were treated over 5 years with dorzolamide versus other hypotensive agents were reviewed. The groups were matched by intraocular pressure, cardiovascular history, and age.